{
    "clinical_study": {
        "@rank": "52084", 
        "acronym": "BEST-CLI", 
        "arm_group": [
            {
                "arm_group_label": "Available vein, open surgical revascularization", 
                "arm_group_type": "Other", 
                "description": "Subjects within the single-segment great saphenous vein cohort who are randomized to best available open surgical revascularization treatment"
            }, 
            {
                "arm_group_label": "Available vein, endovascular revascularization", 
                "arm_group_type": "Other", 
                "description": "Subjects within the single-segment great saphenous vein cohort who are randomized to best available endovascular revascularization treatment"
            }, 
            {
                "arm_group_label": "Alternative conduit, open surgical revascularization", 
                "arm_group_type": "Other", 
                "description": "Subjects within the alternative conduit cohort who are randomized to best available open surgical revascularization treatment"
            }, 
            {
                "arm_group_label": "Alternative conduit, endovascular revascularization", 
                "arm_group_type": "Other", 
                "description": "Subjects within the alternative conduit cohort who are randomized to best available endovascular revascularization treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare the effectiveness of best available surgical treatment with best\n      available endovascular treatment in adults with critical limb ischemia (CLI) who are\n      eligible for either treatment option."
        }, 
        "brief_title": "Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Critical Limb Ischemia", 
        "condition_browse": {
            "mesh_term": "Ischemia"
        }, 
        "detailed_description": {
            "textblock": "Male and female subjects aged 35 years or older will be randomized to receive either open\n      surgical treatment or endovascular treatment.  They will be followed for at least 2 years\n      and up to 4 years after treatment to primarily assess survival and major adverse limb events\n      in the index or treated limb, and secondarily, to determine clinical and cost effectiveness\n      outcomes after treatment.  These outcomes (survival-free of major limb events and clinical,\n      functional and cost effectiveness) will be compared within two cohorts of subjects: those\n      with an available single-segment great saphenous vein, and those with an alternative\n      conduit.  The null hypotheses for both cohorts is that there will be no difference between\n      the best endovascular therapy and the best surgical therapy regarding MALE - free survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age 35 years or older.\n\n          -  Atherosclerotic, infrainguinal PAD (occlusive disease of the arteries below the\n             inguinal ligament caused by atherosclerosis).\n\n          -  CLI, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or\n             rest pain consistent with Rutherford Categories 4-6\n\n          -  Candidate for either open or endovascular infrainguinal revascularization as judged\n             by the treating investigators (see MOO for guidelines on decision-making approach).\n\n          -  Adequate aortoiliac inflow\n\n          -  Adequate popliteal, tibial or pedal revascularization target defined as an\n             infrainguinal arterial segment distal to the area of stenosis/occlusion which can\n             support a distal anastomosis of a surgical bypass.\n\n          -  Willing to comply with protocol, attend follow-up appointments, complete all study\n             assessments, and provide written informed consent.\n\n        Exclusion Criteria:\n\n          -  Disease limited to the femoropopliteal segment with TASC II A pattern (single\n             stenosis <10 cm in length or single occlusion <5 cm in length).\n\n          -  Presence of a femoral, popliteal or tibial aneurysm in the index limb.\n\n          -  Life expectancy of less than 2 years.\n\n          -  Deemed excessive risk for surgical bypass (defined as excessive operative risk by\n             pre-procedural cardiac risk assessment according to established AHA/ACCF criteria).\n\n          -  Planned above ankle amputation on ipsilateral limb within 4 weeks of index procedure,\n             regardless of whether revascularization is performed.\n\n          -  Renal dysfunction (defined as MDRD eGFR \u2264 30 mL/min/1.73 m2 at the time of\n             screening).\n\n          -  Currently on dialysis.\n\n          -  History of renal transplantation.\n\n          -  Presence of a documented hypercoagulable state (defined as a known blood disorder\n             associated with venous or arterial thrombosis).\n\n          -  Non-atherosclerotic occlusive disease (embolic disease, trauma, vasculitis, Buerger's\n             disease) or acute limb-threatening ischemia (defined as tissue loss or ischemic rest\n             pain of less than 14 days duration).\n\n          -  Any prior infrainguinal stenting or stent grafting (with or without atherectomy\n             and/or balloon angioplasty) of the ipsilateral superficial femoral artery and/or\n             above knee popliteal artery.\n\n          -  Any prior percutaneous or surgical intervention involving arteries below the knee\n             joint.\n\n          -  Any of the following procedures performed within 6 months prior to screening:\n\n               -  Percutaneous balloon angioplasty or atherectomy of the superficial femoral\n                  artery and/or above knee popliteal artery;\n\n               -  Common, superficial, or deep femoral endarterectomy;\n\n               -  Femoral to above knew bypass with either venous or prosthetic conduit;\n\n               -  Open surgical inflow procedure (aortofemoral, axillofemoral, iliofemoral or\n                  femorofemoral bypass) involving the index leg\n\n          -  Current immune-suppressive medication, chemotherapy or radiation therapy.\n\n          -  Absolute contraindication to iodinated contrast due to prior near-fatal anaphylactoid\n             reaction (laryngospasm, bronchospasm, cardiorespiratory collapse, or equivalent) and\n             which would preclude patient participation in angiographic procedures.\n\n          -  Known allergy to stainless steel or nitinol.\n\n          -  Pregnancy or lactation.\n\n          -  Administration of an investigational drug for peripheral arterial disease within 30\n             days of randomization.\n\n          -  Participation in a clinical trial (except observational studies) within the previous\n             30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "2100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060630", 
            "org_study_id": "BEST-CLI Trial"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Available vein, open surgical revascularization", 
                    "Alternative conduit, open surgical revascularization"
                ], 
                "intervention_name": "Open surgical revascularization", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Available vein, endovascular revascularization", 
                    "Alternative conduit, endovascular revascularization"
                ], 
                "description": "A variety of FDA approved devices will be used within this treatment arm.  The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.", 
                "intervention_name": "Endovascular revascularization", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Surgical revascularization", 
            "Endovascular revascularization", 
            "Amputation"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Watertown", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02472"
                }, 
                "name": "New England Research Institutes, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia", 
        "overall_contact": {
            "email": "mmontrond@neriscience.com", 
            "last_name": "Maureen Montrond", 
            "phone": "617-972-3285"
        }, 
        "overall_official": [
            {
                "affiliation": "Brigham and Women's Hospital", 
                "last_name": "Matthew Menard, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Boston University", 
                "last_name": "Alik Farber, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Massachusetts General Hospital", 
                "last_name": "Kenneth Rosenfield, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "New England Research Institutes, Inc.", 
                "last_name": "Flora S Siami, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "New England Research Institutes, Inc.", 
                "last_name": "Susan Assmann, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Major Adverse Limb Event (MALE)- free survival", 
            "safety_issue": "No", 
            "time_frame": "At 48 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060630"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical status will be determined by assessing amputation status, myocardial infarction status, stroke status, secondary intervention (major or minor) status in index leg, number of interventions (major and minor) per limb salvaged, hemodynamic failure status, and clinical failure status.", 
                "measure": "Clinical status", 
                "safety_issue": "No", 
                "time_frame": "30 days, 3, 6, 12, 18 and 24 months (30, 36, 42 and 48 months for subjects enrolled early in the trial)"
            }, 
            {
                "description": "Quality of life (QoL) assessments will be determined by using the VascuQoL, EuroQoL EQ-5D, SF-12 questionnaires and (at selected sites) the six-minute walk test.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "30 days, 3, 12, and 24 months (36 and 48 months for subjects enrolled early in the trial)"
            }, 
            {
                "description": "Treatment-associated costs (in- and out-patient) and incremental cost-effectiveness measured in dollars per quality-adjusted life years.", 
                "measure": "Cost-Effectiveness Status", 
                "safety_issue": "No", 
                "time_frame": "30 days, 3, 6, 12, 18 and 24 months (30, 36, 42 and 48 months for subjects enrolled early in the trial)"
            }, 
            {
                "description": "Composite of major adverse limb event (MALE)", 
                "measure": "Major adverse limb event", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Numeric rating scale (NRS) for pain", 
                "measure": "Pain status", 
                "safety_issue": "No", 
                "time_frame": "30 days, 3, 6, 12, 18 and 24 months (36 and 48 months for those enrolled early in the trial)"
            }, 
            {
                "description": "Composite of perioperative death (POD) (death within 30 days of index procedure)", 
                "measure": "Perioperative death", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "New England Research Institutes", 
        "sponsors": {
            "collaborator": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "New England Research Institutes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}